Hope Line Physio

  .  Mechanism & Class Class:  Cardioselective β₁-blocker Action: Blocks cardiac β₁-receptors → ↓ heart rate, ↓ contractility, ↓ renin release Reduces cardiac output →  lowers BP Key Limitation: Lacks vasodilatory effects (unlike carvedilol/nebivolol) Minimal CNS penetration (vs. propranolol) 2.  FDA-Approved Uses Indication Dosage Range Notes Hypertension 25-100 mg daily Not first-line per guidelines Angina Pectoris 50-200 mg daily Reduces attack frequency Arrhythmias 50-100 mg daily SVT/Ventricular control 3.  Dosing Protocol Starting:  25-50 mg once daily Titration:  ↑ by 25 mg weekly (max 100 mg/day) Take:  On empty stomach (food ↓ absorption 20%) Renal Adjustment: CrCl (mL/min) Dose Adjustment 15-35 Max 50 mg/day <15 Max 25 mg/day or avoid 4.  Black Box Warnings & Contraindications Risk Critical Considerations Abrupt Withdrawal ↑ Angina/MI risk – taper over 1-2 weeks Heart Failure Decompensation Avoid in acute HF or HFrEF...

  1.  Mechanism & Class Class:  β₁-Selective Beta-Blocker ( Cardioselective ) Action: Blocks cardiac β₁-receptors → ↓  sinus node firing rate  and  AV conduction Reduces resting/peak heart rate (HR), myocardial oxygen demand Formulations: Tartrate (IR):  Short-acting (dosed BID) -  Lopressor® Succinate (ER):  24-hour control -  Toprol-XL® 2.  Key Indications for Rate Control Condition Target HR Formulation Atrial Fibrillation (AFib) 60-100 bpm Tartrate BID Sinus Tachycardia 60-100 bpm Succinate daily Post-MI Tachycardia 50-60 bpm Tartrate BID → Succinate SVT Acute IV → PO IV/PO Tartrate 3.  Dosing Protocols Scenario Initial Dose Titration Max Dose Chronic AFib Tartrate 25 mg BID ↑ by 25 mg BID q3-7d 100 mg BID Acute SVT/AFib (IV) 2.5-5 mg IV slow Repeat q5min × 3 15 mg Post-MI Tartrate 25 mg BID → Switch to Succinate 100 mg daily 200 mg/day Anxiety-Induced Tachycardia Succinate 25 mg daily ↑ 25 mg weekly 200 mg/day Goal HR:...

  1.  Mechanism of Action Class:  Angiotensin II Receptor Blocker (ARB) Action:  Blocks AT₁ receptors → inhibits angiotensin II-induced: Vasoconstriction Aldosterone secretion Cardiac remodeling Unique Feature:  Partial  PPAR-γ agonist  → improves insulin sensitivity & lipid metabolism. 2.  FDA-Approved Uses Indication Dosage Key Benefit Hypertension (HTN) 40-80 mg once daily 24-hour BP control CV Risk Reduction 80 mg once daily ↓ Stroke/MI in high-risk patients 3.  Dosing & Administration Starting Dose:  40 mg daily Target Dose:  80 mg daily (max) Take:  With/without food, same time daily Titration:  Adjust monthly (full effect in 4-8 weeks) Special Populations: Elderly/Renal/Liver Impairment:  Max 40 mg/day 4.  Key Advantages Feature Clinical Impact 24-hour half-life Superior nocturnal BP control PPAR-γ agonism ↓ Triglycerides, ↑ HDL-C Tissue penetration Protects heart/kidneys No cough  (vs. ACEi) ...